Full Press Release Details
to Present at Bloom Burton & Co. Healthcare Conference
VICTORIA, British Columbia--(BUSINESS WIRE)--April 26, 2017--Aurinia
Pharmaceuticals Inc., (NASDAQ:AUPH)(TSX:AUP) today announced that its
Chief Executive Officer, Richard M. Glickman, will present at the Bloom
Burton & Co. Healthcare Conference in Toronto, Ontario on May 2, 2017 at
11:30am ET. A webcast will be available and can be accessed via the
investor section of the Aurinia website, www.auriniapharma.com. A
replay will also be archived on the site following the event.
Aurinia is a clinical stage
biopharmaceutical company focused on developing and commercializing
therapies to treat targeted patient populations that are suffering from
serious diseases with a high unmet medical need. The company is
currently developing voclosporin, an investigational drug, for the
treatment of lupus nephritis (LN), an inflammation of the kidney caused
by Systemic Lupus Erythematosus (SLE) and represents a serious
progression of SLE. The company is headquartered in Victoria, BC and
focuses its development efforts globally. www.auriniapharma.com.
We Seek Safe Harbor.
Aurinia Pharmaceuticals Inc.
Head of IR & Communications